EPCAM and cancer: Subsequently, MCC cells were treated with a dose range of 0.001–10 nM of EpCAM-ReTARGTPR, EpCAM-ReTARGTPRIFNαR149A, and rhIFNα, respectively, which reduced cancer cell viability by half (Figure 5B).